|
Orthologous residues
|
|
DNA‑PK (human): T2609‑p, DNA‑PK (mouse): T2605‑p, DNA‑PK (rat): T2603‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody, western blotting
|
|
Disease tissue studied:
ataxia-telangiectasia, breast cancer
|
|
Relevant cell lines - cell types - tissues:
CHO (fibroblast), GM02052 (fibroblast), HeLa (cervical), HSF (fibroblast), L3 (lymphoblastoid), MCF-7 (breast cell)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
hamster, human
|
|
Comments:
BT human lymphoblastoid cell line, AT5 (SV-40 transformed A-T cells), 1BR3 human fibroblasts
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
ATM (human)
|
pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme, phospho-antibody, modification site within consensus motif, siRNA inhibition of enzyme, activation of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
ionizing radiation
|
|
|
|
increase
|
|
|
siRNA
|
ionizing radiation
|
ATM (human)
|
|
inhibit treatment-induced increase
|
|
|
KU-55933
|
ionizing radiation
|
|
|
inhibit treatment-induced increase
|
|
|
NU7441
|
ionizing radiation
|
|
|
no effect upon treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (process):
cell growth, altered, chromatin organization, altered
|
|
Comments:
increases survival in ionizing radiation and repairing double strand DNA breaks
|